Targeting energy metabolism in Huntington's disease.
Walker
Francis O
FO
Department of Neurology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA. fwalker@wfubmc.edu
Raymond
Lynn A
LA
D000818:Animals; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism; D018450:Disease Progression; D004734:Energy Metabolism; D005508:Food Deprivation; D006801:Humans; D000071058:Huntingtin Protein; D006816:Huntington Disease / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D007328:Insulin / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D009154:Mutation; D009419:Nerve Tissue Proteins / Q000235:genetics; D009687:Nuclear Proteins / Q000235:genetics; D017374:Paroxetine / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D014451:Ubiquinone / Q000627:therapeutic use; D015431:Weight Loss
D019208:Brain-Derived Neurotrophic Factor; D000071058:Huntingtin Protein; D007328:Insulin; D009419:Nerve Tissue Proteins; D009687:Nuclear Proteins; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors; D014451:Ubiquinone; C086055:HTT protein, human; C506812:Htt protein, mouse